PLSH · XBRL financial data

Panacea Life Sciences Holdings financial statements, every fiscal year

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PLSH's year ends in late December)

In thousands of dollars	FY 2018Dec 31, 2018	FY 2019Dec 31, 2019	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023
Revenue	0	346	2,071	2,060	2,300	—
Revenue from contracts with customers	—	—	—	2,060	1,627	2,385
Cost of revenue	0	1,939	2,302	1,519	1,231	1,263
Cost of goods and services sold	0	2,046	2,720	—	—	—
Gross profit	0	(1,700)	(649)	541	396	1,122
Research and development	300	22	0	—	—	—
General and administrative	1,933	3,272	2,679	1,519	1,093	1,456
Total operating expenses	2,436	9,178	9,906	6,478	6,049	6,668
Other operating income (expense)	—	—	(20)	—	28	—
Operating income (loss)	(2,436)	(10,878)	(10,555)	(5,937)	(5,652)	(5,546)
Interest expense	464	479	1,003	1,105	2,048	1,556
Other income (expense)	(1,901)	654	(387)	—	—	—
Income tax expense (benefit)	0	—	—	—	—	—
Net income (loss)	(4,337)	(10,225)	(10,941)	(4,782)	(9,143)	(8,015)
Earnings per share, basic USD per share	—	—	—	(0.28)	(0.62)	(0.48)
Earnings per share, diluted USD per share	—	—	—	—	(0.62)	(0.48)
Weighted average shares, basic thousands of shares	—	—	—	16,916	14,862	16,627
Weighted average shares, diluted thousands of shares	—	—	—	—	14,862	16,627

Fiscal years (PLSH's year ends in late December)

In thousands of dollars	FY 2018Dec 31, 2018	FY 2019Dec 31, 2019	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023
Cash and cash equivalents	2	18	25	20	7	101
Marketable securities	—	—	2,853	3,791	1,107	15
Accounts receivable	0	56	0	244	206	264
Inventory	0	1,338	11	4,264	4,449	4,014
Prepaid and other current assets	12	249	15	278	113	263
Total current assets	14	2,429	51	9,098	6,382	4,656
Property and equipment, net	0	477	20	8,840	7,676	6,448
Right-of-use asset	0	2,173	0	3,595	3,242	3,865
Goodwill	—	—	2,189	2,189	2,189	3,014
Total assets	14	9,799	71	23,784	19,489	17,983
Accounts payable	923	1,442	2,028	—	—	—
Accrued liabilities	47	358	620	—	283	—
Current portion of long-term debt	—	186	696	—	—	—
Total current liabilities	3,339	4,191	4,905	10,071	15,074	19,448
Lease liability, non-current	0	1,827	0	3,347	2,987	3,254
Total liabilities	3,439	6,117	5,110	16,681	21,634	26,275
Accumulated deficit	(10,538)	(21,129)	(30,384)	(16,765)	(25,908)	(33,923)
Total stockholders' equity	(3,425)	4,219	(3,258)	7,102	(2,145)	(8,291)
Total liabilities and equity	14	9,799	71	23,784	19,489	17,983
Common shares outstanding (cover page) thousands of shares	31,654	45,522	99,633	14,762	14,762	17,645

Fiscal years (PLSH's year ends in late December)

In thousands of dollars	FY 2018Dec 31, 2018	FY 2019Dec 31, 2019	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023
Net income (loss)	(4,337)	(10,225)	(10,941)	(4,782)	(9,143)	(8,015)
Stock-based compensation	227	3,775	1,352	—	—	—
Net cash from operating activities	(466)	(5,746)	(700)	(3,922)	(2,400)	(1,524)
Purchases of property and equipment	0	541	0	163	244	65
Net cash from investing activities	0	(2,041)	0	523	(197)	(65)
Proceeds from issuing equity	0	7,215	385	—	—	—
Net cash from financing activities	307	7,804	706	3,335	2,584	1,684
Net change in cash	—	—	(8,431)	(65)	(13)	94

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Panacea Life Sciences Holdings	108	1,056	(357)	17.6M	0.3 quarters	Q1 FY24 10-QMar 31, 2024
VivoSim Labs	1,670	18	(3,213)	14.9M	0.5 quarters	Q1 FY27 10-QJun 30, 2026
Celldex Therapeutics	47,454	22	(57,410)*	78.5M	12.5 quarters	Q2 FY26 10-QJun 30, 2026
AIM ImmunoTech	9,900	26	(4,590)*	30.4M	2.2 quarters	Q2 FY26 10-QJun 30, 2026
America Great Health	29	26	1.7*	21.2B	—	Q3 FY26 10-QMar 31, 2026
Vyome Holdings	7,888	27	(904)*	7.0M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
Nutra Pharma	not reported	34	(251)*	7.2B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Kaya Holdings	26	5.4	(68)*	686.4M	0.4 quarters	Q3 FY25 10-QSep 30, 2025
One World Products	169	50	(145)*	120.1M	1.2 quarters	Q3 FY25 10-QSep 30, 2025

Not investment advice. Not affiliated with the U.S. SEC.